These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 8701189

  • 1. [Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system].
    Erne P.
    Praxis (Bern 1994); 1996 Feb 20; 85(8):227-33. PubMed ID: 8701189
    [Abstract] [Full Text] [Related]

  • 2. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG, Schencking M, Scheer C, Rupp H.
    Praxis (Bern 1994); 1997 Apr 02; 86(14):566-74. PubMed ID: 9198851
    [Abstract] [Full Text] [Related]

  • 3. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J, Fraccarollo D.
    Minerva Cardioangiol; 2003 Apr 02; 51(2):155-64. PubMed ID: 12783071
    [Abstract] [Full Text] [Related]

  • 4. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 02; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 5. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA, Wendt C, Saborowski F.
    Fiziol Cheloveka; 2005 Jan 02; 31(6):97-105. PubMed ID: 16366159
    [Abstract] [Full Text] [Related]

  • 6. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
    Neves MF, Amiri F, Virdis A, Diep QN, Schiffrin EL, CIHR Multidisciplinary Research Group on Hypertension.
    Can J Physiol Pharmacol; 2005 Nov 02; 83(11):999-1006. PubMed ID: 16391708
    [Abstract] [Full Text] [Related]

  • 7. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH, Voors AA.
    Int J Cardiol; 2006 Jan 26; 106(3):367-72. PubMed ID: 16337046
    [Abstract] [Full Text] [Related]

  • 8. [Role of the cardiac renin-angiotensin system in hypertensive heart disease].
    Holmer SR, Riegger GA.
    Herz; 1995 Oct 26; 20(5):322-9. PubMed ID: 7498879
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE, McKinnie JJ, Greenberg SS, Giles TD.
    Prog Cardiovasc Dis; 1999 Oct 26; 41(4):265-300. PubMed ID: 10362349
    [Abstract] [Full Text] [Related]

  • 10. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences?
    Klotz S, Burkhoff D, Garrelds IM, Boomsma F, Danser AH.
    Eur Heart J; 2009 Apr 26; 30(7):805-12. PubMed ID: 19223317
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 26; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 12. [Growth stimulating properties of angiotensin II on the heart: consequences for therapy of heart failure].
    Schunkert H, Holmer SR, Riegger G.
    Z Kardiol; 1993 Oct 26; 82 Suppl 4():1-6. PubMed ID: 8147057
    [Abstract] [Full Text] [Related]

  • 13. [Pathophysiology of left ventricular hypertrophy in arterial hypertension].
    Vallotton MB, Braconi-Quintaje S, Lang U.
    Praxis (Bern 1994); 1997 Feb 11; 86(7):234-7. PubMed ID: 9139339
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 11; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 16. The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects.
    Falkenhahn M, Gohlke P, Paul M, Stoll M, Unger T.
    J Cardiovasc Pharmacol; 1994 Sep 11; 24 Suppl 2():S6-13. PubMed ID: 7898096
    [Abstract] [Full Text] [Related]

  • 17. Cardiac renin-angiotensin system: role in development of pressure-overload hypertrophy.
    Lorell BH.
    Can J Cardiol; 1995 Aug 11; 11 Suppl F():7F-12F. PubMed ID: 7664219
    [Abstract] [Full Text] [Related]

  • 18. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms.
    Weber KT, Sun Y, Tyagi SC, Cleutjens JP.
    J Mol Cell Cardiol; 1994 Mar 11; 26(3):279-92. PubMed ID: 8028011
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.